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Association of TNF 238 and 308 Promoter Polymorphisms
with Psoriasis Vulgaris and Psoriatic Arthritis but not with
Pustulosis Palmoplantaris
To the Editor:
Overexpression of tumor necrosis factor (TNF)-a is a central
element in the pathogenesis of psoriasis vulgaris (PV) and
psoriatic arthritis (PsA); however, the underlying mecha-
nisms are poorly understood. Several recent studies with
German patients found an association between the rare A
allele of the G ! A single nucleotide polymorphism at po-
sition 238 of the TNFA promoter and psoriasis, particularly
in patients with early disease onset (Arias et al, 1997; Hohler
et al, 1997; Reich et al, 1999; Hohler et al, 2002; Reich et al,
2002). There is also evidence that carriage of the rare A
allele of another G ! A single nucleotide polymorphism at
position 308 of the promoter is decreased in patients with
PsA (Hohler et al, 2002), although within this disease sub-
group it may be increased in patients with a more progres-
sive course of joint involvement (Balding et al, 2003). In light
of the possible influence of TNFA promoter polymorphisms
on cytokine production (Hajeer and Hutchinson, 2001), the
increased formation of TNF-a in psoriasis could at least
partially be genetically determined.
In this study, TNFA 238 and 308 genotypes were
analyzed in 239 unrelated patients with PV, 43 patients with
pustulosis palmoplantaris (PPP) without concomitant PV,
and 135 control subjects according to published methods
(Reich et al, 2002). All participants were Caucasians and
were enrolled at the Department of Dermatology, University
of Tartu, Estonia. Patients with PV were considered to have
early-onset disease if skin symptoms occurred before 40 y
of age, and late-onset disease if age at onset was X40 y
(Henseler and Christophers, 1985). Disease severity was
assessed at study entry by determination of the psoriasis
area and severity index (PASI) (Fredriksson and Pettersson,
1978). PV patients were classified to have concomitant PsA
(n¼59) if this diagnosis had been established by an expe-
rienced rheumatologist. Clinical deformities of the hands
and/or feet consistent with PsA were seen in 23 of these
patients, and nine patients had erosions of the hands and/or
feet by radiographic assessment. Control subjects were
recruited from among medical students, health care per-
sonnel, and patients presenting at the dermatological
outpatient clinic with mild expression of either facial tel-
eangiectasis or skin tags. The study was approved by the
Ethics Review Committee on Human Research of the Uni-
versity of Tartu, and was conducted according to the
Declaration of Helsinki protocols. Informed consent was
obtained from all participants.
To evaluate deviation from the Hardy–Weinberg equilib-
rium, observed and expected genotype frequencies were
compared by a Monte-Carlo goodness-of-fit test in PV and
PPP patients and in controls. Odds ratios (OR) and exact
95% confidence intervals (CI) were calculated to compare
genotype frequencies. Carriage rates of variant allele were
investigated using the exact test by Fisher. To correct for
multiple testing, a hierarchical test strategy was adhered to
as described (Reich et al, 2002), and the respective nominal
p values (pnom) were adjusted according to Bonferroni–
Holm (padj).
Absolute and relative TNFA genotype frequencies are
shown in Table I. The genotypes were in Hardy–Weinberg
equilibrium with the exception of the TNFA 238 locus in
the PPP subgroup (p¼ 0.0118). TNFA genotype frequencies
in the control group were similar to those observed in other
large European studies (Hohler et al, 1997; Reich et al,
2002).
Carriage of TNFA 238A was significantly more com-
mon among patients with PV than among control subjects
(23.8% vs 8.9%; OR 3.21 [1.60–6.84], padj¼0.0012), where-
as carriage of TNFA 308A was decreased (17.6% vs
29.6% in controls, OR 0.51 [0.30–0.86], padj¼0.0360). The
latter finding was independent of TNFA 238 as the differ-
ence between patients and controls remained similar after
exclusion of 238A positive individuals from the analysis
(20.3% vs 30.9% in controls).
Abbreviations: CI, confidence interval; OR, odds ratio; padj, ad-
justed p value; pnom, nominal p value; PASI, psoriasis area and
severity index; PPP, pustulosis palmoplantaris; PsA, psoriatic ar-
thritis; PV, psoriasis vulgaris; TNF, tumor necrosis factor
282 LETTER TO THE EDITOR THE JOURNAL OF INVESTIGATIVE DERMATOLOGY
Pathogenetic similarities between PV and PPP have re-
cently been shown to include the prominent role of TNF-a
(Kitamura et al, 1999). But, in contrast to the findings in PV
patients, carriage rates of TNF 238A and TNF 308A in
patients with PPP were similar to those in the control group
(Table I).
In accordance with previous findings, the association
between TNFA 238A and PV appeared to be more pro-
nounced in patients with a positive family history (30.3% vs
8.9% in controls; OR 4.46 [2.05–10.14], padj¼ 0.0036) than
in those with sporadic disease (19.3% vs controls; OR 2.45
[1.13–5.56], pnom¼0.0155, padj¼ 0.1860). Unlike in earlier
studies (Reich et al, 2002), however, TNFA 238A was
likewise increased in patients with early (o40 y) and late
disease onset (X40 y), and in male and female patients. The
decrease of TNFA 308A was seen in patients with
early and late disease onset, and seemed to be independ-
ent of gender and family history. Due to the smaller
number of individuals in the subgroup analysis, not all as-
sociations remained significant after correction for multiple
testing.
As there is recent evidence that cytokine gene poly-
morphisms may influence disease severity in PV and PsA
(Balding et al, 2003; Kingo et al, 2003), TNFA genotype fre-
quencies were also analyzed separately in patient sub-
groups with mild (PASIo12; n¼ 87) and moderate-to-
severe disease (PASIX12; n¼152). Genotype frequencies
of the TNFA 238 polymorphism were not significantly dif-
ferent in these groups. But, there was a trend toward a
decreased carriage of TNFA 308A in patients with more
severe disease. In patients with mild disease, the carriage
rate of the A allele was 21.8%, and was not significant-
ly different compared with control individuals (29.6%;
OR¼ 0.66 [0.33–1.29], pnom¼ 0.2165), but it was 15.1%
in patients with a PASIX12 (OR¼0.42 [0.23–0.78],
pnom¼ 0.0041, padj¼0.1640 vs controls).
Increased carriage of TNFA 238A in PV patients com-
pared with controls was more pronounced among patients
without arthritis (25.6% vs 8.9% in controls; OR 3.52 [1.73–
7.62], padjo0.0001) than among patients with arthritis
(18.6% vs 8.9%; OR 2.35 [0.87–6.24], padj¼ 0.4376), while
the finding of a decreased carriage of TNFA 308A was
more pronounced among patients with arthritis (13.6% vs
29.6%; OR 0.37 [0.14–0.89], pnom¼0.0187, padj¼0.5236)
than among patients without joint involvement (18.9% vs
29.6%; OR 0.55 [0.32–0.97], pnom¼ 0.0316, padj¼0.7584).
Within the subgroup of patients with arthritis, however,
TNFA 308A appeared to be increased in individuals with
more severe joint disease, i.e., patients with deformities of
the hands and/or feet or radiologically confirmed erosions
(Fig 1).
In conclusion, we confirm and extend previous observa-
tions on the role of TNFA promoter polymorphisms in pso-
riasis and postulate that (i) carriage of TNFA 238A is
associated with PV in Caucasian populations, whereas car-
riage of TNFA 308A may have a protective effect and is
associated with less severe skin disease, that (ii) PPP, at
least the PPP variant without concomitant PV, is genetically
different from PV, and that (iii) although carriage of TNFA
308A is decreased in PsA compared with controls, within
patients with arthritis, it may be a marker of more severe
joint involvement. With therapies that antagonize TNF-a
becoming a more widely used strategy to treat psoriatic
skin and joint symptoms, it will be interesting to see whether
the presence of TNFA promoter polymorphisms influences
the response to treatment. Our study supports the concept
of a differential role of TNFA polymorphisms in PV and PsA
and encourages future investigations in the field.
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Table I. Frequencies of TNFA 238 and TNFA 308 genotypes




(n¼ 239) (n¼43) (n¼135)
n (%) n (%) n (%)
TNFA 238 G/G 182 (76.3) 42 (97.7) 123 (91.1)
G/A 55 (23.0)a 0 12 (8.9)
A/A 2 (0.8) 1 (2.3) 0
TNFA 308 G/G 197 (82.4) 32 (74.4) 95 (70.4)
G/A 41 (17.2)b 11 (25.6) 39 (28.9)
A/A 1 (0.4) 0 1 (0.7)
aOdds ratio¼ 3.21, 95% confidence interval¼ 1.60–6.84, nominal p-
value¼ 0.0003, adjusted p-value¼ 0.0012; TNF 238G/A and A/A
psoriasis vulgaris vs control.
bOdds ratio¼0.51, 95% confidence interval¼ 0.30–0.86, nominal p-
value¼ 0.0090, adjusted p-value¼ 0.0360; TNF 308G/A and A/A



































































Carriage rate of TNFA 308A is increased in patients with severe
psoriatic arthritis. Carriage of TNFA 308A in patients with psoriasis
with (PsA pos.) or without (PsA neg.) a confirmed diagnosis of psoriatic
arthritis, as well as in patients with PsA with or without clinical de-
formities or bone erosions of the hands and/or feet. Bars represent the
percentage of carriers of TNFA 308A in each of these groups
and in control subjects. n, number of individuals investigated in each
group.
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Upregulation of CD44 and Hyaluronate Synthases by Topical
Retinoids in Mouse Skin
To the Editor:
CD44 is a ubiquitously expressed cell surface proteoglycan
that exists as numerous alternatively spliced and/or post-
translationally modified variants (Stamenkovic et al, 1991;
Screaton et al, 1992; Lesley et al, 1993; Bennett et al, 1995;
Zhou et al, 1999). CD44 appears to be a major cell surface
receptor for hyaluronate [(HA); Aruffo et al, 1990; Miyake
et al, 1990]. In a recent study, we have shown that two major
functions of CD44 in the mouse skin are the regulation of
keratinocyte proliferation in response to extracellular stimuli
and the maintenance of local HA homeostasis (Kaya et al,
1997).
HA is a high-molecular-weight linear polymer composed
of repeating units of D-glucuronic acid and N-acetyl-D-glu-
cosamine and is the principal component of the extracel-
lular matrix (Fraser and Laurent, 1989; Laurent and Fraser,
1992). HA is synthesized by hyaluronate synthase (HAS) at
the inner surface of the plasma membrane as long chains by
adding sugar residues at the reducing end, and then ex-
truded to the extracellular space (Prehm, 1984). Recently,
three distinct yet highly conserved genes encoding mam-
malian HAS, HAS1, HAS2, and HAS3, have been cloned
(Itano and Kimata, 1996; Spicer et al, 1996, 1997). In vitro
studies demonstrated that HAS enzymes are distinct from
each other in enzyme stability, elongation rate of HA, Km
values for D-glucuronic acid and N-acetyl-D-glucosamine,
and average chain length of synthesized HA (Itano et al,
1999). All HAS isoenzymes are expressed in the monolayers
of rat keratinocytes (Pienimaki et al, 2001), whereas human
keratinocytes are reported to express only HAS1 and HAS3
(Sayo et al, 2002) and mouse skin at least HAS1 and HAS2,
HAS1 being expressed more strongly in the epidermis and
HAS2 in the dermis (Sugiyama et al, 1998).
It has been shown that HA was selectively stimulated by
retinoids in porcine epidermis (King, 1984), hairless mouse
skin (Margelin et al, 1996), and human epidermis in skin
organ culture (Tammi et al, 1989). The mechanism of this
stimulation is not known. CD44 and HA expression show a
close correlation in human epidermis (Wang et al, 1992) and
rat epidermal keratinocyte organotypic cultures (Pasonen-
Seppanen et al, 2003). The effect of retinoids on CD44 and
HAS expression, which might contribute to retinoid-induced
HA stimulation, has not been studied.
In this study, we analyzed the effect of a topical retinoid,
retinaldehyde (RAL), on the protein and RNA expression of
CD44 and the RNA expression of HAS1, HAS2, and HAS3
in mouse skin. Pilot observations were also made in hu-
man skin on the CD44 protein expression. The experi-
ments described in the article were approved by
the Ethical Commission on Animal Experimentation of the
University of Geneva and the Cantonal Veterinary Office
of Geneva. The Guidelines on Animal Experimentation of
the Cantonal Veterinary Office of Geneva in accordance
with the Federal Legislation of Swiss Confederation were
followed.
Immunostaining of vehicle-treated back skin of SKH1
hairless mice revealed the standard expression of CD44 in
Abbreviations: HA, hyaluronate; HAS, hyaluronate synthase; RAL,
retinaldehyde
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